about
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library.A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infectionCarcinoembryonic antigen as a target to induce anti-tumor immune responses.Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral VaccineThe extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in miceAnaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo.MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cellsHelper cell-independent antitumor activity of potent CD8(+) T cell epitope peptide vaccines is dependent upon CD40L.IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.Searching for the Achilles Heel of FOXP3Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells.Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice.A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats.In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1.Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.Identification and characterization of a T-helper peptide from carcinoembryonic antigen.CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.Inhibitory effect against polymerase and ribonuclease activities of HIV-reverse transcriptase of the aqueous leaf extract of Terminalia triflora.Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcinoembryonic antigen.Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes.Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.
P50
Q27472875-B032F6A1-AC6F-49DA-943E-B8D90EA355BFQ27485419-32177A48-E911-4A26-85B0-0D238B3D0387Q31039313-09C2FF81-EEAA-43E8-8290-7A61A091F541Q33297446-3EB37884-9C0C-4BE6-B645-F396678501D3Q33703557-98C8D1D3-91F3-4A7A-A286-1CA17D4007E8Q33762936-B59EE35A-B9BB-4BC9-98F6-BBC09D00DF3AQ33845287-7D8E4178-79E8-4B75-A65A-D500A3BB6655Q34681370-72A7D31F-2EDE-4388-AC8F-16A3A8AE864CQ35785085-E1464EFD-787F-47EB-A03D-0AEF796B7627Q35867122-8916D670-95B9-48AD-B261-E1A172980E15Q36107133-4351F45F-0FE1-4EDE-9DBE-61EEE17AC439Q36161454-6294BFE0-BC75-4E59-BEF8-27E02684D710Q36338990-DC5D43E2-856D-4F83-9A0B-22B6522212CAQ36710936-24125C3D-392E-4D2B-93BA-42BA8F5A601DQ37182767-69200051-17D9-451F-BD3B-EC54A891FBCEQ37268962-C6F7A8CD-8253-4AF7-ADA1-379FDEB2C087Q37499652-A145C97B-7950-4A13-AB6A-E9E4BD736851Q37709350-7C38B8A5-428F-45C1-87FE-7EBF9C228F4FQ38172210-1E7CD3EF-433B-4E1C-B43F-E90C92B53315Q38587418-1C86D194-176D-4727-B572-B4B507FFFFA5Q38726869-1E4BB80B-21B6-4BAC-A42B-E9590819E997Q38758212-B55700B0-5D4F-4957-ABE9-4845DDA638F6Q38767792-0E45E881-318C-4BA7-A4AD-16782E55B02CQ38775981-A9676506-23F2-4207-8B07-0A4C499E2A05Q39000980-8C5E6623-6C3D-4420-A034-605D0197238AQ39674562-57677C9E-4943-4EE2-98D0-B2C4C08210D8Q39914658-2F087E38-C42F-4287-B377-0A16155AC809Q39970343-83D65117-EB0A-466D-8A15-35FFCFAC80C4Q40066956-4CA71527-A433-4814-BE5E-D089D9F221B9Q40070362-5E68EDA0-A286-4744-A2E2-506F84834794Q40129030-793D7067-304D-4CB3-BD5F-B30364A386E5Q40175332-D28E6EB0-3C23-4307-84AC-9A5DB19CA3C9Q40564055-FD0DCF5A-9215-4850-8162-651BA1B61179Q40614121-8311A379-9836-4D2C-8B78-3346E9B44B37Q40686571-97D68F39-111A-44D8-9B1F-EF924E845AC2Q40687703-E6ED765A-733E-4897-8292-A209527B5620Q40759589-2F4A85B8-DFFE-449C-BB53-A2FB7BDE6493Q40815800-339F1D56-A45A-4624-9F23-5A7C835240C4Q40910301-89419931-A7BC-466A-B04E-A19A40A8DBDEQ40961624-485BF22C-3454-43DE-8C4E-42DCFF7591DF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan José Lasarte
@ast
Juan José Lasarte
@en
Juan José Lasarte
@es
Juan José Lasarte
@sl
type
label
Juan José Lasarte
@ast
Juan José Lasarte
@en
Juan José Lasarte
@es
Juan José Lasarte
@sl
prefLabel
Juan José Lasarte
@ast
Juan José Lasarte
@en
Juan José Lasarte
@es
Juan José Lasarte
@sl
P106
P21
P31
P496
0000-0003-1641-3881